
自引率: 1.5%
被引量: 10912
通过率: 暂无数据
审稿周期: 1
版面费用: 暂无数据
国人发稿量: 暂无数据
投稿须知/期刊简介:
Journal of Internal Medicine, with its International Advisory Board has developed into a highly successful journal since it was first published in its revised form in 1989. The Journal publishes original clinical work within internal medicine and its sub-specialities, in addition to work from adjacent fields. It features original articles, case reports, review articles, together with an Editorial in every issue, commenting upon current topical problems.Two special lines of information carried by the Journal are the Minisymposium and the Frontiers in Medicine series. The former consists of four to five articles analysing an actual problem from various angles; and the latter of one longer article of a review character.
期刊描述简介:
Journal of Internal Medicine, with its International Advisory Board has developed into a highly successful journal since it was first published in its revised form in 1989. The Journal publishes original clinical work within internal medicine and its sub-specialities, in addition to work from adjacent fields. It features original articles, case reports, review articles, together with an Editorial in every issue, commenting upon current topical problems.Two special lines of information carried by the Journal are the Minisymposium and the Frontiers in Medicine series. The former consists of four to five articles analysing an actual problem from various angles; and the latter of one longer article of a review character.
-
Tadalafil use is associated with a lower incidence of Type 2 diabetes in men with benign prostatic hyperplasia: A population-based cohort study.
被引量:- 发表:1970
-
Regarding: Adherence to guideline-recommended care of late-onset hypertension in females versus males: A population-based cohort study.
被引量:- 发表:1970
-
Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin-K antagonists: A retrospective German claims data analysis.
Vitamin-K antagonists (VKAs) have widely been replaced by non-VKA oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as VKA, instead of warfarin, the much longer-acting phenprocoumon is used, which was not compared to NOACs in clinical trials. Using administrative data from a large German health insurance, we included all anticoagulation-naïve patients with a first prescription of a NOAC or VKA between 2012 and 2020. We analysed overall survival, major adverse cardiac and cerebrovascular events, major thromboembolic events and major bleeding. Overall, 570,137 patients were included (apixaban: 26.9%, dabigatran: 4.6%, edoxaban: 8.8%, rivaroxaban: 39.1% and VKA: 20.7% of these 99.4% phenprocoumon). In the primary analysis using a 1:1 propensity score matching-cohort (PSM-cohort), a significantly higher overall mortality was found for apixaban, edoxaban and rivaroxaban (all p < 0.001) but not for dabigatran (p = 0.13) compared to VKA. In this PSM-cohort, 5-year mortality was 22.7% for apixaban versus 12.7% for VKA, 19.5% for edoxaban versus 11.4% for VKA, 16.0% for rivaroxaban versus 12.3% for VKA (all p < 0.001) and 13.0% for dabigatran versus 12.8% for VKA (p = 0.06). The observed effect was confirmed in sensitivity analyses using un-weighted and three different weighted Fine-Gray regression models on the basis of the entire cohort. In this large real-world analysis, apixaban, edoxaban and rivaroxaban, but not dabigatran, were associated with worse survival compared to VKA. These findings, consistent with a few other studies including phenprocoumon, cast profound doubts on the unreflected, general use of NOACs. Randomized trials should assess whether phenprocoumon might actually be superior to NOACs.
被引量:- 发表:1970
-
Role of NO pathway in the clinical picture of idiopathic systemic capillary leak syndrome.
被引量:- 发表:1970
-
Impact of cancer on the mortality of patients with idiopathic inflammatory myopathies by flexible parametric multistate modelling.
Patients with idiopathic inflammatory myopathies (IIM) have an increased risk of cancer, but their cancer-related disease burden remains unclear. To explore how cancer might impact the mortality of patients with IIM and examine the associated prognostic factors for cancer and death. We identified patients with IIM diagnosed between 1998 and 2020 and ascertained their cancer and death records via linkage to the Swedish healthcare and population registers. Transition hazards from IIM diagnosis to cancer and death were estimated in multistate models using flexible parametric methods. We then predicted the probability of having cancer or death, and the duration of staying alive at a given time from IIM and cancer diagnoses from a crude model. We also explored prognostic factors for progression to cancer and death in a multivariable model. Of 1826 IIM patients, 310 (17%) were diagnosed with cancer before and 306 (17%) after IIM diagnosis. In patients diagnosed with cancer after IIM, the 5-year probability of death from cancer and from other causes was 31% and 18%, respectively, compared to 7% and 15% in patients without cancer after IIM. We reported several factors associated with risk of progression to cancer and death. Specifically, patients with first cancer after IIM who were older at IIM diagnosis, had cancer history, dermatomyositis and a cancer diagnosis within 1 year following IIM faced a greater cancer-specific mortality. We observed a substantial increase in mortality from cancer, compared to before, rather than other causes after a cancer diagnosis following IIM, suggesting an unmet medical need for effective cancer management in IIM patients. This finding, along with the identified prognostic factors, provides useful insight into future research directions for improving cancer management in IIM patients.
被引量:- 发表:1970